NASH Observatory

⏿ The PanNASH Initiative is an interactive web-based platform presenting global NASH statistics to inform NASH control and research.

Significant fatigue and pruritus are common in patients with advanced NASH

Although early stages of NASH may not be associated with severe symptoms, it is increasingly appreciated that NASH is not an asymptomatic disease. In fact, systematic assessments of patients with NASH using validated health-related quality- of-life instruments suggest significant impairment of patient-reported outcomes...
Read MoreSignificant fatigue and pruritus are common in patients with advanced NASH

Impact of Ramadan fasting on NASH severity

The aim of the current study by A. Mari et al. (Nazareth Hospital EMMS, Nazareth, and Faculty of Medicine in the Galilee, Bar-Ilan University, Safed, Israel) was to assess the impact of caloric restrictions during Ramadan fasting on severity index of NASH severity scores. The authors conducted a retrospective, case control study in Nazareth Hospital...
Read MoreImpact of Ramadan fasting on NASH severity

Review: Non-invasive tests of hepatic steatosis and fibrosis: confounding factors

Non-invasive tests of NAFLD can be classified by the target disease state or the type of test. Disease states of interest include the detection of hepatic steatosis (for the diagnosis of NAFLD or using steatosis improvement as treatment outcomes in early phase studies)...
Read MoreReview: Non-invasive tests of hepatic steatosis and fibrosis: confounding factors

Review: Tumour incidence in patients with NAFLD

The spectrum that ranges from non-alcoholic fatty liver disease (NAFLD) to the more aggressive form of non-alcoholic steatohepatitis (NASH) all the way to liver cirrhosis is associated with complications and hepatocellular carcinoma. Extrahepatic malignancies are among the leading causes of death in patients with NAFLD, but little is known about...
Read MoreReview: Tumour incidence in patients with NAFLD

NAFLD and heart failure with preserved LV ejection fraction

The prevalence of NAFLD in heart failure preserved left ventricular ejection fraction (HFpEF) patients could reach 50%. Therefore, NAFLD is considered an emerging risk factor. The purpose of this review by R. Itier et al. (Department of Cardiology, CHU, Toulouse, France) is to provide an overview of the relationships between NAFLD...
Read MoreNAFLD and heart failure with preserved LV ejection fraction

Review: outcome of hepatocellular carcinoma in patients with NAFLD

Background: This systematic review and meta-analysis by KM Chin et al. (Singapore General Hospital, Singapore) aimed to compare the outcomes of curative therapy for hepatocellular carcinoma from NAFLD and non-NAFLD aetiologies. They pooled and examined findings for 5579 patients from 9 studies...
Read MoreReview: outcome of hepatocellular carcinoma in patients with NAFLD

Extrahepatic manifestations of NAFLD: a review

Diagnosis and management of extrahepatic manifestations of NAFLD are crucial for the treatment of these patients. These manifestations include cardiovascular disease, type 2 diabetes mellitus, metabolic syndrome, chronic kidney disease, obstructive sleep apnea, polycystic ovarian syndrome, hypothyroidism, psoriasis, and extrahepatic malignancy...
Read MoreExtrahepatic manifestations of NAFLD: a review

Kupffer cells and development of liver fibrosis in NASH

Although recent evidence suggests the involvement of iron accumulation in the pathogenesis of NASH, the underlying mechanisms remain poorly understood. Previously, Y. Kanamori et al. (Nagoya, Japan) reported a unique histological structure termed ‘‘crown-like structure (CLS),’’ where liver-resident macrophages (Kupffer cells) surround...
Read MoreKupffer cells and development of liver fibrosis in NASH

NAFLD: a year in review

he field of NAFLD and its progressive form, NASH, has, despite the challenges of the COVID-19 pandemic, continued to rapidly evolve in 2020. There have been substantial advances in NAFLD mechanisms, diagnostics, and treatment. Key developments include the identification of a multiparametric cellular and tissue signature to define disease progression...
Read MoreNAFLD: a year in review